key: cord-0695498-1a0h7uce authors: Alketbi, Eman Humaid; Hamdy, Rania; El‐Kabalawy, Abdalla; Juric, Viktorija; Pignitter, Marc; A. Mosa, Kareem; Almehdi, Ahmed M.; El‐Keblawy, Ali A.; Soliman, Sameh S. M. title: Lipid‐based therapies against SARS‐CoV‐2 infection date: 2021-01-13 journal: Rev Med Virol DOI: 10.1002/rmv.2214 sha: 5f920912bce2400d2afc74ad5a1b07306a083676 doc_id: 695498 cord_uid: 1a0h7uce Viruses have evolved to manipulate host lipid metabolism to benefit their replication cycle. Enveloped viruses, including coronaviruses, use host lipids in various stages of the viral life cycle, particularly in the formation of replication compartments and envelopes. Host lipids are utilised by the virus in receptor binding, viral fusion and entry, as well as viral replication. Association of dyslipidaemia with the pathological development of Covid‐19 raises the possibility that exploitation of host lipid metabolism might have therapeutic benefit against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). In this review, promising host lipid targets are discussed along with potential inhibitors. In addition, specific host lipids are involved in the inflammatory responses due to viral infection, so lipid supplementation represents another potential strategy to counteract the severity of viral infection. Furthermore, switching the lipid metabolism through a ketogenic diet is another potential way of limiting the effects of viral infection. Taken together, restricting the access of host lipids to the virus, either by using lipid inhibitors or supplementation with exogenous lipids, might significantly limit SARS‐CoV‐2 infection and/or severity. Coronaviruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are family of enveloped viruses 1 (Figure 1 ). The virion production involves major changes in the host cellular lipidome. 2, 3 Since coronaviruses lack the basic metabolic processes, 4, 5 they manipulate the host lipid metabolism in various stages of the life cycle. 6 Viral infections modify the host lipid synthesis, transportation and metabolism for its replication and to get the lipids required for the formation of their envelopes and double membrane vesicles (DMV). 5 The lipids are critically required for virus invasion, attachment, fusion and replication. 7 Lipids play crucial role as source of energy and signalling in SARS-CoV-2 life cycle. 8 Therefore, we aimed to study the importance of host lipids in SARS-CoV-2 infection in order to explore novel therapeutic host lipid targets for the development of effective, broad spectrum and safe antiviral therapies and to avoid the evolved drug resistance by the virus. A significant elevated lipogenesis has been observed as a sign of SARS-CoV-2-infection. 2 Lipidomics changes associated with Covid-19 disease give mechanistic insight about the optimal lipid microenvironment required during the viral infection. Shen et al. 9 reported a significant alteration in the serum lipid levels of SARS-CoV-2-infected patients when compared to healthy individuals ( Figure 2 ). They reported a significant decrease in over 100 lipids including sphingolipids, glycerophospholipids and fatty acids in the serum of SARS-CoV-2-infected patients. 9 Similarly, Hu et al. 10 showed that total cholesterol (TC), high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol levels were sharply decreased in the serum of infected patient when compared to healthy control. On the other hand, lipidomics analysis of virusinfected alveolar cells showed significant increase in multiple lipid pathways ( Figure 2 ) and lipid modifying enzymes. 11 A significant reduction in the serum lipid levels of Covid-19 patients was observed, which is dramatically associated with the severity of the disease symptoms. 12 The progression in SARS-CoV2 infection is associated with the leaking of plasma lipids and cholesterol into the alveolar space. 12 However, the signal leading to the transport of lipids from blood to alveolar space is not yet identified. The occupancy of angiotensin-converting enzyme 2 (ACE2) receptor by the viral glycoprotein may be a major signal, particularly that the increase in lung cholesterol can result in increasing the ACE2 trafficking to the infection site. 13 Although the intra-alveolar microenvironment is separated from the systemic circulation, it is believed that neutral fat, cholesterol (free and esterified forms) and phospholipids (PLs) are transported in the circulation combined with one another and with lipoproteins as macromolecular complexes. 14 Alveolar type II (ATII) cells have long been known to bind and take up lipoproteins, including HDL, LDL and very LDL (VLDL), and to resecrete PLs and cholesterol, [15] [16] [17] which are mostly used up to support the viral infection at the alveolar cells. The increase in lipid metabolism following viral infection indicated that the virus highjacks the host cells to utilize the host lipids for their own propagation. The aforementioned data indicated the importance of host lipids and their relocalisation to the site of viral infection. Further, viral binding may signal the transportation of lipids from the circulation to the alveolar space. Here, we are proposing that viral binding, entry and replication disrupt the lipids balance at the alveolar space, site of infection, leading to transportation of lipids from the circulation to the alveolar space. In order to explain this mechanism, the importance of host lipids to the virus is highlighted. Surfactant is the major component within the lung defence system that has unique properties displaying both lung stabilizing and F I G U R E 1 Structural features SARS-CoV-2 F I G U R E 2 SARS-CoV-2 infection altered the host lipid metabolism antimicrobial properties. 18 Surfactant is synthesised within the ATII epithelial cells. 19 Surfactant is actively being secreted and its materials are constantly being exchanged and recycled into the ATII cells to maintain constant surfactant pool size, 20,21 while some materials can be degraded by alveolar macrophages (AM) to lipids that can support the viral infection ( Figure 3 ). These lipids include palmitic acid (PA), phosphatidyl choline (PC) and cholesterol. Pulmonary surfactant is a complex mixture of lipids and proteins that forms a film lines the alveolar air-surface interface and protect the lungs from pathogen invasion. 21 Disruption of surfactant lipids can disturb the surface tension lowering ability and allow the pathogens entry. 22 However, the process by which the virus penetrates the surfactant and reaches the ATII cells is not known. Several studies demonstrate that human viruses including SARS-CoV-2 can significantly alter surfactant phospholipids composition and causing loss of surfactant and hence promote the viral penetration. 23 On the other hand, binding of surfactant proteins (SP), which importantly contribute to the surfactant behaviour as a defence system, 24, 25 to the virus occurs by recognition of hemagglutinin and neuraminidase glycans on the surface of the virus, thereby hindering the ability of the virus to enter the cell. 26 However, the hemagglutinins found on SARS-CoV-2 exhibit antigenic variations that resulted in reduced binding, leading to greater virulence and subsequent high mortality and morbidity in patients. 26 SARS-CoV-2 hemagglutinin-esterase (HE) provides classical glycan-binding lectin activity, while exhibiting hemagglutination and destruction of the surfactant proteins 27 (Figure 1 ). 4.2.1 | Host lipids potentiate the viral attachment and entry to ATII cells Viral attachment to the host cell receptor is lipid-dependent. 28 The entry of SARS-CoV-2 is mediated by the binding of viral spike (S) protein to ACE2 receptor, which is localised in cholesterol-rich microdomains within the lipid rafts 29 (Figure 3 ). Lipid rafts are regions of the plasma membrane characterised by high concentrations of sphingolipids (sphingomyelin and sphingoglycolipids) and cholesterol. 30 Therefore, cholesterol increases the expression of ACE2 receptor and hence facilitates the interaction between the S protein and ACE2 receptor. 28 S-palmitoylation is a unique protein lipidation process essential for viral invasion. 31 S-palmitoylation of SARS-CoV-2 S protein has been reported to facilitate its anchor and fusion with the host cellular membrane receptor ( Figure 3 ). Furthermore, it has been reported that the HDL scavenger receptor B type 1 (SR-B1) facilitates ACE2-dependent uptake of SARS-CoV-2 by augmenting the virus attachment to ATII cells. 32 Viral internalisation process occurs by the fusion of the envelope lipid with the plasma membrane, which is mediated by endocytosis. Inhibition of viral endocytosis by cholesterol depletion indicates the importance of raft-mediated endocytosis for the viral entry. 33 Coronaviruses hijack the host cells for the formation of replication and transcription complex, the double membrane vesicles (DMVs). 34, 35 Formation of DMVs is a key factor for viral replication that provides a favourable barrier to protect the viral replication compartments from the host innate immune responses. 36 DMVs formation requires specific lipid compositions, the unsaturated lysophospholipids ( Figure 3 ). 37 Coronaviruses manipulate the host cellular pathways particularly the lipid metabolism and lipid trafficking to ensure the availability of required lipids for DMVs formation ( Figure 3 ). 38 DMVs biogenesis is a complex process that critically requires modification of lipid composition either via lipid transfer proteins sterol regulatory element-binding proteins (SREBP) or lipid biosynthesis via cellular cytosolic phospholipase A2α enzyme (cPLA2α). 39 SREBPs play essential role in the formation of DMVs, viral protein palmitoylation and viral replication. 40 cPLA2α is a crucial lipid processing enzyme that plays a critical role in the formation of DMVs ( Figure 3 ). 41 Inhibition of SREBPs and cPLA2α can be employed as potential strategy to eradicate coronavirus. Furthermore, viruses stimulate the synthesis of lipid components including in particular lysophospholipids (LPLs) to support the rapid DMVs biogenesis. Therefore, inhibition of LPL synthesis resulted in loss of DMVs and dramatic reduction in viral replication (Figures 3 and 4) . 42 Viruses access the energy required for their replication and assembly via lipid droplets. Lipid droplet serve as storage of neutral lipid including triglycerides and cholesterol esters, which can be employed for energy production, signalling and cell immune response. 43 Furthermore, several studies confirmed that enveloped viruses including coronaviruses are developed or bud from the lipid rafts. 30, 47 Virus enhances the intracellular transportation of host lipids A quick process for the intracellular lipids transportation is required to support the process of viral replication, which is achieved by nonvesicular lipid transfer proteins (LTPs). Viruses hijack the LPTs to mobilize the lipids required for the formation of replication organelles. Cholesterol is transported by oxysterol binding protein (OSBP), 48 while ceramide transportation occurs by ceramide transfer protein (CERT). 49 Both are significantly required in viral replication. Furthermore, Niemann-pick C (NPC) is required to carry and transfer the free and recycled cholesterol to the site of replication. Biosynthesis of fatty acids is initiated by the carboxylation of citrate with acetyl CoA carboxylase to malonyl-CoA, which is then converted to PA by FASN ( Figure 5 ). PA is then elongated and converted to diacylglycerols and then TAGs by DGAT1. PA serves as precursor for the biosynthesis of phospholipids and sphingolipids. 45 Cholesterol-lowering agents can inhibit the optimum lipid microenvironment required for viral infection ( Figure 6 and Table 1 ). Methylβ-cyclodextrin interacts with the lipid raft via its lipophilic core, and hence competes with the viral binding site 51 (Figure 7 and Table 1 ). On the other hand, statins inhibit HMGR enzyme, the rate-limiting Since ZDHHC5 S-palmitoyltransferase is important for viral S protein attachment. It can be a potential therapeutic target for the inhibition of SARS-CoV-2 infection. 31 2-Bromopalmitate was confirmed as a candidate compound to inhibit S-palmitoylation 58 ( Figure 6 and Table 1 ). Endocytosis is a pH-dependent process, which is facilitated by cysteine proteases, such as cathepsin B or L, allowing the release of viral nucleocapsid into the cytoplasm. Chloroquine neutralizes the endosome-lysosomal acidic pH and thus blocks the protease activity and viral internalisation. 50 On the other hand, PVS34 perturbs the structure of viral membrane ( Figure 6 and Table 1 ). PVS34 inhibits the phosphoinositide (PI) 3-kinase centres, which functions in autophagy, and endocytosis. VPS34 inhibits the required membranes components needed for the formation of SARS-CoV-2 particles. 59 Triacsin C blocks the lipid droplet formation through the inhibition of triglycerides-modulating enzymes particularly the long chain fatty acyl CoA synthetase. 60 A922500 is a potent DGAT inhibitor that can inhibit the lipid droplet formation and hence can stop the production of infectious progeny from SARS-CoV-2-infected cells 60 ( Figure 6 and Table 1 ). AM580, a stable retinobenzoic acid derivative, exhibits potent antiviral activity by blocking the activation of SREBP pathway and hence inhibits DMVs formation 4 ( Figure 6 and Table 1 ). Betulin inhibits SREBP cleavage and maturation. 61 cPLA2α inhibitor such as pyrrolidine-2 significantly decreases the formation of DMVs 41 ( Figure 6 and Table 1 ). Phosphatidylinositol-4-phopshate is a potent membrane modifiers that can interfere with the formation of DMVs. Table 1 ). source of LA, which accounts for more than 50% of the lipid content in plant seed oil such as nuts. 67 SARS-CoV-2-infection is associated with an increase in the levels of lipid-modifying enzymes including the fatty acid synthetase enzyme (FASN), 45 and HMGR, the rate-limiting enzyme in cholesterol synthesis and the activation of transcriptional factor SERBP, which regulates the synthesis of cholesterol. 68 SARS-CoV-2 infection also caused an increase in the production of inositol (PI), ceramide sphingolipid, phosphatidyl choline, lysophosphatidyl inositol and lysophatidylcholine. 69, 70 Collectively, disruption of the aforementioned lipid microenvironments can significantly inhibit SARS-CoV-2 infection. Lipid-lowering agents such as statins can inhibit HMGR, and hence inhibit cholesterol biosynthesis, leading to disturbance in lipid raft formation, inhibition of viral replication and immunomodulation activity. 71 Fibrates are triglyceride-lowering agents that target the fatty acid synthesis and showed potent antiviral activity ( Figure 6 and Table 1 ). Annexin A2 is a natural inhibitor of PCSK9, a cholesterol homeostasis regulator, which was recommended with statin in the treatment of Covid-19 patients. 72 Viral nsp3 activates fatty acid synthesis. 73 Therefore, the use of FASN inhibitors such as the natural product cerulenin and the synthetic inhibitor C75 can be employed as potential anti-SARS-CoV-2 drugs ( Figure 6 and Table 1 ). 74 Stearoyl-CoA desaturase1 (SCD1) is the rate-limiting step in MUFA and PUFA biosynthesis. The piperazine derivative A939572 is SCD1 inhibitor, suggesting its potential antiviral activity ( Figure 6 and Table 1 ). 75 Fingolimod ( Figure 6 ) is a sphingomimetics drug employed in clinical trial for the treatment of Covid-19 due to its selective inhibition activity of S1P1 (sphingosine-1-phosphate-1) and its immunosuppressive activity in the late severe infection via the inhibition of TLR-mediated immune response (Table 1 ). 50 LJ001 is a membrane-binding compound that is selectively targets the viral unsaturated phospholipids and inhibits viral entry. 50 Unfortunately, LJ001 shows poor physiological stability, and hence used as lead compound for the development of more effective and stable antiviral drugs such as LJ103 (Figure 7 ). PUFAs including docosahexaenoic acids (AA, DHA, omega-3 fatty acid), and eicosapentaenoic acid were consistently upregulated in cells infected with the virus. 79 It has been shown that PUFAs can inactivate SARS-CoV-2 by blocking the viral proliferation and by inducing the leakage and lysis of viral envelope. 80 Therefore, PUFAs supplementation can help in reducing the sus- Eicosanoids are proinflammatory mediators and signalling molecules that elevated in SARS-CoV-2 infected cells (Table 2) . 81 Further, AA is an endogenous antiviral compound released by the immune cells in response to viral infection in order to inactivate SARS-CoV2. 82 Therefore, its exogenous supplementation can provide an inhibition activity to SARS-CoV-2 (Table 2) . It has been shown that LA can tightly bind with the three composite pockets present on S protein, forming a complex that interrupts the binding with ACE2 receptor. 84 Therefore, LA intake, alone or more likely when synergised with remdesivir, can lead to efficient suppression of SARS-CoV-2 replication. 84 LA is an essential "omega-6" fatty acid that must be obtained from the diet, since it cannot be synthesised in the human body (Table 2) . Therefore, the proper intake of these PUFAs can result in significant reduction in the viral loads and hence can decrease the morbidity and mortality associated with SARS-CoV-2 infection. 82 Glycerophospholipids are essential structural and functional components of the cellular membrane. Cellular phospholipase, cPLA2α, releases lysophospholipids and free fatty acids from glycerophospholipids-based membranes. 41 The released small bioactive lipid molecules (LA and AA) are required together with the produced lysophospholipids to form the specialised DMVs, required in viral replication ( Figure 4) . 41 It has been reported that inhibition of cPLA2α resulted in a significant reduction in lysophospholipids, DMV formation and viral replication in infected cells. 41 Yan et al. 64 reported that lysophospholipids and FAs downstream of cPLA2 activation are upregulated following the HCoV-229E infection. Therefore, the upregulation of these lipid species including LA and AA were believed to promote the efficient coronavirus replication. 64 However, they have noticed a significant reduction in virus replication when they exogenously supplemented to HCoV-229E-or MERS-CoV-infected cells 64 (Figure 4 ). This indicated that exogenous supplementation of these FAs can disrupt the equilibrium between membrane phospholipids and lysophospholipids and hence interfere with the optimal replication of the virus. In addition, supplementation of LA and AA can disturb the LA-AA metabolism and can result in feedback reversion of lysophospholipids to phospholipids through Lands' cycle ( Figure 4 ). 85 LA (C18:3) and AA (C20:4) are among the essential fatty acids that must be provided in human's diets. 86 affected by environmental conditions including drought, 91 temperature 92 and salinity. 92 Therefore, it is important to assess the precise amounts of fatty acids from different regions in order to administer the right dose at the right condition. Switching the host metabolism from carbohydrate-dependent glycolytic state to fat-dependent ketogenic state can significantly affect the viral replication. 93 Supplementation of medium-chain triglycerides such as lauric acid can result in significant reduction in viral envelope formation. Therefore, it can be employed as prophylactic strategy for normal people and adjunct therapy in case of infected individuals. 93 SARS-CoV-2 infection is associated with depleted surfactant. Therefore, it has been suggested that supplementation with synthetic surfactant, KL4 (a mix of DPPC, palmitoyl-oleoyl phosphatidylglycerol, PA and 21-amino acid synthetic peptide) can play a protective role in Covid-19 pandemic. 94 The pathogenicity of SARS-CoV-2 is associated with excessive inflammation, oxidative stress and release of cytokines. Imbalance between proinflammatory, anti-inflammatory eicosanoids is initiated in Covid-19 disease. 95 AA-derived autacoids or eicosanoids are inflammatory lipid mediators. 81 AA is metabolised by epoxygenase to epoxyeicosatrienoic acids (EET). EET is inflammatory regulator that reduces the stress-based cytokines release. 81 However, EET is mainly converted to dihydroxyeicosatrienoic acids by the soluble epoxide hydrolase (sEH), and hence increases the release of cytokines. Therefore, inhibition of sEH can increase the EET level, and hence can suppress the release of IL-6 and activation of NF-kB 81 (Table 3) . EET can shift the AA metabolism to proresolving lipid mediators such as lipoxin, resolvin, protectins and meostasis. Proresolving lipids can restore the normal balance and protect the lung. Lipoxin controls the inflammation without imparting immunosuppression activity. 96 Omega-3 fatty acids are rich in EET that possess anti-inflammatory activity ( Table 3 ). 81 Oleoylethanolamide (OEA) is a cannabinoid derived from oleic acid. It has potential removal activity of respiratory pathogen and can attenuate the inflammatory responses due to SARS-CoV-2 infection (Table 3) . 97 Further, OEA can decrease TLR expression; thus reducing IL-6 and TNF-α during SARS-CoV-2 infection. TLR can initiate the proinflammatory cytokines release. In summary, SARS-CoV-2 infection is associated with host lipids migration from the circulation to the alveolar space in order to support the viral invasion and pathogenicity. In response, host lipids biosynthesis and release are enhanced to cover the viral needs. Furthermore, lipids such as AA and LA are released to limit the inflammation at the initiation of infection. Therefore, restricting the viral access to the host lipids either by applying specific inhibitors or supplementation with specific lipids can be of great importance to limit the viral infection and severity of disease. A novel coronavirus outbreak of global health concern Rhinovirus induces an anabolic reprogramming in host cell metabolism essential for viral replication Building viral replication organelles: close encounters of the membrane types SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target Identification of host cell factors associated with astrovirus replication in caco-2 cells Virus impact on lipids and membranes Role of lipids in virus replication Targeting host lipid flows: exploring new antiviral and antibiotic strategies Proteomic and metabolomic characterization of COVID-19 patient sera Low serum cholesterol level among patients with COVID-19 infection in Wenzhou Host lipidome analysis during rhinovirus replication in HBECs identifies potential therapeutic targets Hypolipidemia is associated with the severity of COVID-19 Clinical features of patients infected with 2019 novel coronavirus in Wuhan The circulating lipids and lipoproteins in coronary artery disease Interaction of lipoproteins with type II pneumocytes in vitro: morphological studies, uptake kinetics and secretion rate of cholesterol Very low density lipoproteins stimulate surfactant lipid synthesis in vitro Low density lipoprotein-and high density lipoprotein-mediated signal transduction and exocytosis in alveolar type II cells Surfactant and its role in the pathobiology of pulmonary infection Pulmonary surfactant in respiratory syncytial virus bronchiolitis: the role in pathogenesis and clinical implications Pulmonary surfactant: functions and molecular composition Molecular and cellular processing of lung surfactant 1 Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids Human adenovirus modulates surfactant phospholipid trafficking Surfactant protein C: its unique properties and emerging immunomodulatory role in the lung Recent advances into understanding some aspects of the structure and function of mammalian and avian lungs The ability of pandemic influenza virus hemagglutinins to induce lower respiratory pathology is associated with decreased surfactant protein D binding CoV-2 evolutionary adaptation toward host entry and recognition of receptor O-acetyl sialylation in virus-host interaction The important role of lipid raftmediated attachment in the infection of cultured cells by coronavirus infectious bronchitis virus beaudette strain Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity Viral membranes A metabolic modeling approach reveals promising therapeutic targets and antiviral drugs to combat COVID-19 HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19 Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex Competitive fitness in coronaviruses is not correlated with size or number of doublemembrane vesicles under reduced-temperature growth conditions Organelle-like membrane compartmentalization of positive-strand RNA virus replication factories Viral rewiring of cellular lipid metabolism to create membranous replication compartments Host lipids in positivestrand RNA virus genome replication Membrane heist: coronavirus host membrane remodeling during replication SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver Inhibition of cytosolic phospholipase A2α impairs an early step of coronavirus replication in cell culture Double-membrane vesicles as platforms for viral replication The expanding role of sphingolipids in lipid droplet biogenesis Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators ssRNA virus and host lipid rearrangements: is there a role for lipid droplets in SARS-CoV-2 infection? Ozone: a potential oxidant for COVID-19 virus (SARS-CoV-2) Do lipid rafts mediate virus assembly and pseudotyping May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection? +) RNA virus replication compartments: a safe home for (most) viral replication The role of lipid metabolism in COVID-19 virus infection and as a drug target Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? Methylbeta-cyclodextrins: the role of number and types of substituents in solubilizing power Novel broad spectrum virucidal molecules against enveloped viruses HIV: a raft-targeting approach for prevention and therapy using plant-derived compounds Phytosterols and their derivatives: structural diversity, distribution, metabolism, analysis, and health-promoting uses Elovanoids downregulate canonical SARS-CoV-2 cell-entry mediators and enhance protective signaling in human alveolar cells Inhibition of acid sphingomyelinase blocks infection with SARS-CoV-2 2-Bromopalmitate and 2-(2-hydroxy-5-nitro-benzylidene)-benzo [b] thiophen-3-one inhibit DHHC-mediated palmitoylation in vitro Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques Limonoid compounds inhibit sphingomyelin biosynthesis by preventing CERT proteindependent extraction of ceramides from the endoplasmic reticulum Expedient and practical synthesis of CERT-dependent ceramide trafficking inhibitor HPA-12 and its analogues Characterization of the lipidomic profile of human coronavirus-infected cells: implications for lipid metabolism remodeling upon coronavirus replication COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status The influence of lysolipids on the spontaneous curvature and bending elasticity of phospholipid membranes Dietary linoleic acid and human health: focus on cardiovascular and cardiometabolic effects Do viruses subvert cholesterol homeostasis to induce host cubic membranes? LPS elevates ceramide levels through regulating ORMDL3 expression in macrophages and acute respiratory distress syndrome model Changes in lipid metabolism in patients with severe COVID-19 Multifaceted roles for lipids in viral infection Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic The envelope protein of severe acute respiratory syndrome coronavirus interacts with the non-structural protein 3 and is ubiquitinated Lipid involvement in viral infections: present and future perspectives for the design of antiviral strategies Piperazine derivatives for therapeutic use: a patent review (2010-present) COVID-19-associated dyslipidemia: implications for mechanism of impaired resolution and novel therapeutic approaches Coronavirus nsp6 proteins generate autophagosomes from the endoplasmic reticulum via an omegasome intermediate A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy Lipidomic profiling reveals significant perturbations of intracellular lipid homeostasis in enterovirusinfected cells What about COVID-19 and arachidonic acid pathway? Eicosanoids: the overlooked storm in COVID-19? Can bioactive lipids inactivate coronavirus (COVID-19) Bioactive lipids in COVID-19-further evidence Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein Metabolic interactions between the Lands cycle and the Kennedy pathway of Glycerolipid synthesis in Arabidopsis developing seeds Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases Lipid concentrations of wild edible Greens in crete Mediterranean wild edible plants: weeds or Variation of seed oil content, oil yield, and fatty acids profile in Iranian Nigella sativa L. landraces Phytochemical contents of five Artemisia species Canola responses to drought, heat, and combined stress: shared and specific effects on carbon assimilation, seed yield, and oil composition Protective role of selenium in Canola (Brassica napus L.) plant subjected to salt stress Switching host metabolism as an approach to dampen SARS-CoV-2 infection SURFACTANTS VERSUS COVID-19 Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition: considerations during the COVID-19 crisis Immunometabolic role of longchain omega-3 fatty acids in obesity-induced inflammation Oleoylethanolamide, a bioactive lipid amide, as a promising treatment strategy for coronavirus/covid-19 Lipid-based therapies against SARS-CoV-2 infection The authors acknowledge the generous support from Sandooq Al-Watan and University of Sharjah to Sameh S. M. Soliman. The authors declared that there are no conflict of interests. Shifts the AA metabolism towards the formation of protective prosolving lipid mediators.Inhibition of sEH will increase the ETT level and subsequently decreases the IL-6 level and NF-Kb activation� Decreases the TLR expression � Its downregulation can increase the stress and inflammation response.Exogenous administration of OEA 10 -ALKETBI ET AL. Eman Humaid The data that support the findings of this study are available within this article. Sameh S. M. Soliman https://orcid.org/0000-0002-7691-615X